@Article{Cakal2020,
journal="Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej",
issn="1734-9338",
volume="16",
number="4",
year="2020",
title="Long-term comparison of everolimus- vs. 
novolimus-eluting bioresorbable vascular scaffolds 
in real world patients",
abstract="The largest amount of evidence for bioresorbable vascular scaffold (BVS) use in clinical practice derives from Absorb trials and registries. Comparison of Absorb BVS with metallic stents resulted in increased rates of target lesion failure and device thrombosis in the Absorb BVS group. We investigated whether all BVS platforms created equal outcomes. At 3-year follow-up novolimus-eluting BVS (Desolve Elixir Medical Corp., Sunnyvale, CA) achieved better outcomes compared with Absorb BVS. The scaffold thrombosis rate is still high with Absorb BVS despite pre- and post- dilatation. No scaffold thrombosis was present with Desolve BVS.",
author="Cakal, Beytullah
and Cakal, Sinem
and Karaca, Oguz
and Omaygenc, Mehmet
and Yilmaz, Filiz
and Gunes, Haci
and Ozcan, Ozgur
and Yıldırım, Arzu
and Boztosun, Bilal",
pages="391--398",
doi="10.5114/aic.2020.101763",
url="http://dx.doi.org/10.5114/aic.2020.101763"
}